一图看懂瑞博生物-B(6938.HK)IPO

Group 1 - Rebio Biopharma-B (6938.HK) has officially launched its IPO, planning to globally offer 27.4874 million H-shares at a price of HKD 57.97 per share, with the subscription period from December 31, 2025, to January 6, 2026, and expected trading to commence on January 9, 2026 [1][5][6] - The company, founded in 2007, focuses on the research and development of small nucleic acid drugs, particularly siRNA therapies, with a core product RBD4059 targeting FXI for thrombotic diseases [7][10][21] - Rebio has a robust pipeline with seven self-developed drug assets in clinical trials, addressing cardiovascular, metabolic, renal, and liver diseases [9][10] Group 2 - The global small nucleic acid drug market is projected to grow significantly, with a compound annual growth rate (CAGR) of 21.6% from 2019 to 2024, and 29.4% from 2024 to 2029 [14] - The company utilizes its proprietary RiboGalSTAR™ platform for liver-targeted drug development, which enhances delivery efficiency and specificity [15][20] - Rebio has received five IND/CTA approvals from regulatory authorities in 2024, including four for Phase II clinical trials, indicating strong progress in its clinical development [16] Group 3 - RBD4059 is the first siRNA drug in clinical stages for treating thrombotic diseases, showing significant efficacy in reducing FXI activity by up to 91.6% in clinical trials [26] - The drug's long-acting formulation allows for administration every 3-6 months, potentially improving patient compliance compared to traditional anticoagulants [28] - RBD5044, targeting high triglycerides, is the second siRNA drug in clinical development, demonstrating strong triglyceride-lowering effects and good safety profiles [30][34] Group 4 - The company has established a global R&D center in Sweden, Ribocure AB, which includes a clinical trial unit (CTU) for conducting independent clinical trials [40] - Rebio has formed strategic partnerships with major pharmaceutical companies, including Boehringer Ingelheim, to enhance its growth prospects and leverage its siRNA technology [41]